Dyslipidemia

The FDA accepted the NDA for olezarsen, an RNA-targeted medicine, in familial chylomicronemia syndrome for priority review, with a PDUFA date set for December 19, 2024.

The latest in our series of quizzes on the ESC/EAS 2019 Dyslipidemia guidelines tests your knowledge on pharmacotherapy recommendations from the document!

Machine learning outperformed clinical diagnostic criteria and the recommended screening criteria in the United Kingdom in identifying familial hypercholesterolemia.

Vutrisiran achieved statistically significant reductions in primary and all secondary endpoints for patients with ATTR-CM in the HELIOS-B trial.

An analysis of patients with acute coronary syndrome shows women receive less lipid-lowering therapy and are less likely to meet LDL-C targets than men.

Zerlasiran, a siRNA agent, significantly reduced lipoprotein(a) levels by approximately 90% at 48 weeks in high-risk cardiovascular patients, per phase 2 data from Silence Therapeutics.

Check out the second quiz in our series testing your knowledge of the ESC/EAS 2019 guidelines on dyslipidemia. This quiz focuses on risk assessment and stratification!

Data from a new study details the apparent benefit of adding polygenic risk scores to improve cardiovascular risk stratification.

Analysis of NHANES data from 1999 to 2020 provides some evidence of diet quality improvement but highlights low rates of adults achieving ideal diet quality.

An analysis of real-world data from propensity score-matched pairs of breast cancer patients treated with anthracyclines suggests statin use was associated with an 18% reduction in all-cause mortality.

Check out the first in our series of quizzes testing your knowledge the ESC/EAS 2019 guidelines on dyslipidemia. this quiz focuses on basic lipid management principles!

New research reveals that elevated lipoprotein(a) and oxidized phospholipids are independent risk factors for early-stage heart failure progression.

A new study suggests the AHA's PREVENT risk calculator may reduce statin use for primary prevention, affecting eligibility for millions of adults.

A study found that only 0.32% of 1.2 million patients underwent Lp(a) testing, with non-Hispanic Black and Hispanic patients significantly less likely to receive the test compared to White patients.

Our cardiology month in review spotlights the top 5 storylines that defined cardiology during May 2024, including new HCM guidelines, news from ESA 2024, and the FLOW trial.

Topline data from the pivotal Phase 3 trial show plozasiran met the primary endpoint of triglyceride-lowering in patients with the ultrarare genetic disease.

Results from a Phase I trial showed significant LDL-C reduction with AZD0780 plus statin therapy in treatment-naive patients with hypercholesterolemia.

Blocking IL-33 production with statins may be an effective preventive strategy to suppress chronic inflammation and the development of certain cancers.

Robert Rosenson, MD, discusses the results of the ARCHES-2 trial and how it informs the potential of ANGPTL3 inhibition as well as RNAi therapies.

Robert Rosenson, MD, discusses the unmet need in mixed hyperlipidemia and the potential for RNA interference therapies in this patient population.

Alirocumab added to high-intensity statin therapy did not further improve endothelial function in patients with acute myocardial infarction.

A phase 2 trial suggests zodasiran significantly reduces triglycerides in patients with mixed hyperlipidemia, showing dose-dependent improvements in lipid profiles.

Phase 2b study results show that investigational plozasiran significantly reduced triglyceride-rich lipoproteins in patients with mixed hyperlipidemia.

A new study found a greater PCSK9 is associated with a greater cutaneous melanoma risk.

ORION-8 demonstrates the consistent long-term efficacy and tolerability of twice-yearly inclisiran over a mean cumulative exposure of 3.7 years.